Articles by PR Newswire Releases

No Picture
News

Gladstone Investigator to Direct UCSF’s Graduate Program in Biological and Medical Informatics

December 11, 2019 PR Newswire Releases Comments Off on Gladstone Investigator to Direct UCSF’s Graduate Program in Biological and Medical Informatics

Katherine Pollard becomes director of the Biological and Medical Informatics Graduate Program at UC San Francisco

SAN FRANCISCO, Dec. 11, 2019 /PRNewswire/ — In search of treatments for human diseases, medical researchers rely on the latest technol… […]

No Picture
News

Anpac Bio Appoints Nobel Prize Winner Dr. Michael Levitt As Chief Consultant To Lead Anpac’s Pioneering Efforts In Cancer Screening

December 11, 2019 PR Newswire Releases Comments Off on Anpac Bio Appoints Nobel Prize Winner Dr. Michael Levitt As Chief Consultant To Lead Anpac’s Pioneering Efforts In Cancer Screening

SAN JOSE, Calif., Dec. 11, 2019 /PRNewswire/ — Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio” or the “Company”) announced today the appointment of Professor Michael Levitt of Stanford University to be the Chief Consultant of Anpac Bio’s Innovatio… […]

No Picture
News

BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate Update

December 10, 2019 PR Newswire Releases Comments Off on BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate Update

SAN JOSE, Calif., Dec. 10, 2019 /PRNewswire/ — BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter en… […]

No Picture
News

Verantos Receives a Grant from the National Institutes of Health (NIH) to Fund Advanced Clinical Phenotyping in Real World Evidence Studies

December 10, 2019 PR Newswire Releases Comments Off on Verantos Receives a Grant from the National Institutes of Health (NIH) to Fund Advanced Clinical Phenotyping in Real World Evidence Studies

PALO ALTO, Calif., Dec. 10, 2019 /PRNewswire/ — Verantos, the market leader in regulatory-grade real world evidence (RWE) studies, today announced that it has received a grant from the National Institutes of Health (NIH), National Center for Advan… […]

No Picture
News

An Agency of the U.S. Federal Government Selects Cloud-based ValGenesis VLMS to Digitalize Their Validation Lifecycle Processes

December 10, 2019 PR Newswire Releases Comments Off on An Agency of the U.S. Federal Government Selects Cloud-based ValGenesis VLMS to Digitalize Their Validation Lifecycle Processes

SAN FRANCISCO, Dec. 10, 2019 /PRNewswire/ — ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that an Agency of the U.S. Federal Government has chosen ValGenesis’s cloud-based, 100% p… […]

No Picture
News

U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder

December 10, 2019 PR Newswire Releases Comments Off on U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder

VistaGen’s PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 /PRNewswire/ — VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-sta… […]

No Picture
News

Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

December 9, 2019 PR Newswire Releases Comments Off on Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

– Interim Phase 2a Data Demonstrate Improved Overall Response Rate in Combination with Rituximab — 48% Overall Response Rate Observed in Cerdulatinib Only; 76% Overall Response Rate Observed with Cerdulatinib in Combination with Rituximab –

SOUTH SA… […]

No Picture
News

Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting

December 9, 2019 PR Newswire Releases Comments Off on Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting

SAN FRANCISCO, Dec. 9, 2019 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, … […]

No Picture
News

IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020

December 9, 2019 PR Newswire Releases Comments Off on IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020

– Targeting initiation of Phase 2 single-arm potentially registration-enabling clinical trial in MUM in Q1 2020, potentially coinciding with Phase 2 introduction of tablet formulation- Pharmacokinetic Phase 1 clinical sub-study with immediate release… […]